Xiyuan Anjian Medicine (Shanghai) Co., Ltd.

Plus, news about Tarsus Pharmaceuticals and Biohaven: Brise Pharmaceuticals raises $20M: The funding comes from Shunxi Fund, Sherpa Healthcare Partners and Qiming Ventures, among other investors. The Shanghai-based company is developing therapies for acute and chronic pain. It began an early-stage clinical study of a chronic low back pain treatment in the US last year. — Lei Lei Wu Taro shareholder rebels against Sun Pharma’s buyout offer: Krensavage Asset Management — Taro Pharmaceutical Industries’ largest minority shareholder — said the generics maker’s proposed buyout is based “on an investment bank’s flawed analysis.” Back in January, Sun announced it would convert its majority ownership of Taro into a full takeover, paying $43 a share in cash for shares that it doesn’t already own. According to Krensavage, the deal undervalues Taro by roughly 44%. — Katherine Lewin

SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by Shunxi Fund, followed by Cnfuel Capital, Vinner Therapeutics and existing investors such as Qiming Venture Partners and BioTrack Capital. The Pre-A+ round is exclusively invested by Sherpa Healthcare Partners. Brise has advanced two molecules to the clinical stage in US and China. The funds raised will be used to advance the company's product pipeline in the preclinical and clinical stages, as well as to further refine and validate the Trigeminovascular System (TVS) biology-based drug development platform and the Dorsal Root Ganglion (DRG) biology-based drug development platform. Brise, led by CEO Dr. Guochun Li, stands as a clinical-stage biopharmaceutical company with a singular focus on the development of innovative and highly differentiated analgesic treatments for debilitating pain conditions with large unmet needs, placing a particular emphasis on addressing migraine, neuropathic and musculoskeletal pain. The organization's vision is to provide safe, effective, and accessible pain relief solutions for the multitude of patients worldwide grappling with poorly managed pain conditions. SOURCE Brise Pharmaceuticals Co., Ltd

SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for chronic pain, has taken a significant step forward with the commencement of dosing for the initial participants in its Phase 1 clinical trial, designated MBR01T-101. The trial focuses on the safety and tolerability study of BR01T, a groundbreaking monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA) for addressing Chronic Low Back Pain (CLBP). The MBR01T-101 trial, structured as a randomized, double-blind, and placebo-controlled study, aims to enroll approximately 56 patients with chronic low back pain. The trial is set to be conducted at a prestigious JBR CenExel clinical research center located in Salt Lake City, Utah, USA. The primary objectives of this trial are to assess both the safety and effectiveness of the BR01T treatment in patients with chronic low back pain. Dr. Eric Liu, Chief Medical Officer of Brise Pharmaceuticals, expressed enthusiasm about this significant stride, stating, "Starting this first-in-patient study of BR01T is a major milestone for Brise Pharma, as we advance our clinical portfolio into the realm of chronic pain conditions. An anti-TrkA antibody holds the promise to revolutionize the landscape of chronic low back pain by providing sustained relief. Our overarching goal is to empower chronic low back pain sufferers around the globe to regain control of their lives through the potential of BR01T." About Brise Pharmaceuticals Brise Pharma stands as a clinical stage biopharmaceutical company with a singular focus on the development of innovative and highly distinct analgesic treatments for severe pain conditions, placing a particular emphasis on addressing issues such as migraine, inflammatory pain, and neuropathic pain. The organization's vision encompasses the provision of safe, effective, and accessible pain relief solutions for the multitude of patients worldwide grappling with debilitating pain conditions. About BR01T Brise Pharmaceuticals' lead program, BR01T, represents a revolutionary anti-TrkA antibody with the potential to redefine the treatment landscape for CLBP. This target mechanism has garnered robust validation through preclinical and clinical data. What sets BR01T apart is its selective impact on crucial signaling pathways, facilitating optimal pain relief without the possible occurrence of bone-related side effects, such as bone damage. Furthermore, BR01T's inhibition of TrkA in both acute and chronic painful states introduces a novel mechanism of action that stands distinct from traditional opioids or nonsteroidal anti-inflammatory drugs (NSAIDs). About MBR01T-101 CLBP Clinical Study Chronic Low Back Pain (CLBP) constitutes a widespread and incapacitating condition affecting millions across the globe. Characterized by pain in the lower back that extends beyond a 12-week duration, CLBP lacks a specific underlying cause or disease. This condition exerts profound effects on affected individuals' quality of life, physical function, mental well-being, and socioeconomic status. The complexities of CLBP encompass a multifaceted interplay of biological, psychological, and environmental factors. Effective management necessitates a comprehensive, multidisciplinary approach tailored to each patient's preferences and needs. The core objectives of the MBR01T-101 clinical study encompass pain reduction, enhanced functionality, and the prevention of chronicity and disability. For media inquiries, please contact: Haosi Chen General Manager Assistant Email: [email protected] SOURCE Brise Pharmaceuticals Co., Ltd